EVMN vs LLY
EVMN: Evommune is a clinical-stage biotech focused on developing innovative oral and injectable therapies to address unmet needs in chronic inflammatory diseases like atopic dermatitis and migraine. LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies.
Side-by-side fundamentals
| Metric | EVMN | LLY | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $5.38 | $1,283.66 | |
| Market cap | $195M | $1.21T | |
| P/E as of 2026-10-20 | n/a | 43.09 | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | n/a | 0.87 | |
| Net margin FY2025, SEC XBRL | -529.8% | +31.7% | LLY higher |
| Operating margin FY2025, SEC XBRL | -623.6% | n/a | |
| ROE FY2025, SEC XBRL | -33.5% | +77.8% | LLY higher |
| ROA FY2025, SEC XBRL | -30.6% | +18.4% | LLY higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 1.62 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +85.7% | +44.7% | EVMN higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +31.7% | |
| Dividend yield as of 2026-09-03 | n/a | +0.6% | |
| Dividend streak (yrs) SEC XBRL | 0 | 10 | LLY higher |
| Beta as of 2026-09-03 | 1.03 | 0.54 | |
| 1-year return as of 2026-10-20 close | n/a | +58.7% |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.